Why More Patients Are Getting an MRI Before Their First Biopsy

Until relatively recently, most men being evaluated for possible prostate cancer went to biopsy without first having an MRI. Today MRI is often used earlier, although the pathway still varies between patients and health systems.

That variation can be confusing. Two men with similar prostate-specific antigen (PSA) results, measured by a blood test, may receive different advice. One is sent for an MRI first. Another proceeds directly to biopsy, or has additional blood or urine testing first.

None of these pathways is wrong. They reflect improvements in imaging, evolving evidence, regional guidance, local resources, and the fact that prostate cancer risk cannot be judged from one number alone.

Prostate MRI gives physicians a detailed view of the gland before tissue is removed.

Multiparametric MRI (mpMRI) combines several image types: T2-weighted (T2W) images showing anatomy, diffusion-weighted imaging (DWI) and apparent diffusion coefficient (ADC) maps reflecting how water moves through tissue, and dynamic contrast-enhanced (DCE) images taken after an injected contrast agent. Biparametric MRI (bpMRI) generally omits the contrast sequence.

MRI may show suspicious areas and their locations, lesion size and imaging characteristics, prostate volume, and changes related to benign prostatic hyperplasia (BPH, a non-cancerous enlargement common with age).

Radiologists commonly describe how suspicious an area appears using the Prostate Imaging Reporting and Data System (PI-RADS), which runs from 1 to 5.

In the UK, NICE recommends reporting pre-biopsy mpMRI on a 5-point Likert scale, which allows clinical context to be weighed alongside imaging appearance. A PI-RADS or Likert score is not the same as a diagnosis.

When MRI identifies a suspicious area, the physician may direct biopsy needles toward that location. This is called an MRI-targeted biopsy. It may be done by visually matching the MRI to ultrasound images, by using MRI-ultrasound fusion software, or by performing the biopsy inside the MRI scanner.

Major trials, including PROMIS and PRECISION, helped establish MRI's role before an initial biopsy, showing that an MRI-based pathway could improve detection of clinically significant cancer, generally Grade Group 2 or higher, while reducing some unnecessary biopsies and diagnoses of lower-risk disease.

Targeted sampling does not always replace systematic sampling. Research has shown that targeted and systematic approaches each identify cancers the other misses, so depending on MRI findings, prior biopsy history, and overall risk, a physician may take targeted samples alone or combine the two.

A negative MRI lowers risk, but it does not reduce the risk to zero.

In selected patients, an MRI without a suspicious lesion may support a shared decision to defer biopsy and continue PSA monitoring. That decision depends on the full clinical picture, which may include the PSA result and trend, PSA density, prostate volume, PI-RADS or Likert score, age and life expectancy, family history, race or ancestry where clinically relevant, prior biopsy history, symptoms and other conditions, selected biomarkers or inherited genetic findings, and patient preferences.

PSA density can help place a PSA result into context. It divides the PSA level by the prostate volume measured on imaging. Two illustrative examples, both using a PSA of 6.0 ng/mL:

• Prostate volume of 60 cc: 6.0 ÷ 60 = 0.10 ng/mL/cc
• Prostate volume of 30 cc: 6.0 ÷ 30 = 0.20 ng/mL/cc

NICE refers to a PSA density above 0.15 ng/mL/cc as one marker of stronger suspicion. These figures are illustrative and should be interpreted by a physician.

Similar PSA and MRI results can therefore mean different things in different men. AUA/SUO guidance notes that when a man remains at elevated risk despite an unremarkable MRI, systematic biopsy is still warranted.

When biopsy is deferred, follow-up matters. A physician may recommend repeat PSA testing, reassessment of PSA density, another MRI, or further evaluation as things change over time.

_{For more information about prostate size and density, see: What Does Your Prostate Size Actually Tell Your Doctor?}

Professional guidance reflects different evidence standards, health systems, and available resources.

• United States: the 2026 AUA/SUO guideline states that clinicians may use MRI before an initial biopsy to improve detection of Grade Group 2 or higher cancer. The wording leaves room for clinical judgment rather than requiring MRI for every patient.
• Europe: the 2026 EAU guideline strongly recommends MRI before biopsy for patients with suspected organ-confined disease, and allows biopsy to be omitted with PSA monitoring in selected patients whose MRI and other risk factors indicate low clinical suspicion.
• United Kingdom: NICE recommends mpMRI as the first-line investigation for suspected clinically localised prostate cancer, and advises considering omission of biopsy after a low-risk Likert score only after the risks and benefits have been discussed and a shared decision reached.

Practical factors matter too: MRI access and waiting times, insurance or reimbursement, scan quality, local radiology and biopsy expertise, clinical urgency, and the patient's overall health and preferences.

A different recommendation does not automatically mean that one physician is ignoring evidence. It may reflect a different combination of risk, resources, regional guidance, and clinical circumstances.

AI-supported analysis may add another layer of review by helping identify suspicious imaging patterns, outline the prostate and possible lesions, estimate volume, and highlight regions that may deserve closer attention. How much it improves real-world outcomes is still being studied. It does not confirm cancer or determine whether a biopsy or treatment is needed, and physician interpretation remains central.

For men who already have a prostate MRI, DeepView Imaging provides an AI-supported second analysis powered by ProstatID, AI software from Bot Image that is FDA-cleared, CE-Marked, and UKCA-Certified for prostate MRI analysis. It analyzes T2W, DWI, and ADC images, so it works with both bpMRI and mpMRI scans, and produces a report with color overlays that can be shared with a radiologist, urologist, or treating physician.

This offers another perspective on information already contained in the MRI. It does not replace the original radiology interpretation, biopsy pathology, or physician judgment, and the cleared intended use states that patient-management decisions should not be based solely on the ProstatID analysis.

The growing use of MRI before prostate biopsy reflects better imaging, stronger evidence, and an effort to make biopsy decisions better informed.

MRI can help identify suspicious areas, guide targeted sampling, estimate prostate volume, and place PSA density into context. In some men with a reassuring MRI and low overall risk, it may support a discussion about monitoring rather than immediate biopsy. In others, biopsy may still be appropriate even when MRI does not show a suspicious area.

No single test, including PSA, PSA density, MRI, PI-RADS, biomarkers, or AI-supported analysis, can diagnose or rule out prostate cancer by itself. Your physician can interpret these findings together and explain how they apply to you.

For more perspectives, check out the following articles:

• _{Why MRI Before Biopsy Changes Everything}
• _{Why MRI + AI Before Biopsy Improves Patient Outcomes}